GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lophos Holdings Inc (XCNQ:MESC) » Definitions » Asset Impairment Charge

Lophos Holdings (XCNQ:MESC) Asset Impairment Charge : C$0.00 Mil (TTM As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Lophos Holdings Asset Impairment Charge?

Lophos Holdings's Asset Impairment Charge for the three months ended in Mar. 2024 was C$0.00 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Mar. 2024 was C$0.00 Mil.

Lophos Holdings Asset Impairment Charge Historical Data

The historical data trend for Lophos Holdings's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lophos Holdings Asset Impairment Charge Chart

Lophos Holdings Annual Data
Trend Mar22 Mar23 Mar24
Asset Impairment Charge
- - -

Lophos Holdings Quarterly Data
Dec21 Mar22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Asset Impairment Charge Get a 7-Day Free Trial Premium Member Only - - - - -

Lophos Holdings Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.00 Mil.

Lophos Holdings Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of Lophos Holdings's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

Lophos Holdings Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lophos Holdings Inc (XCNQ:MESC) » Definitions » Asset Impairment Charge
Comparable Companies
TSXV:IOT TSX:APLI XCNQ:MBIO TSXV:RP XCNQ:NOVA XCNQ:BIOV XCNQ:GLOW TSXV:MRVL TSXV:RKV TSX:IPCI OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
1111 Melville Street, Suite 620, Vancouver, BC, CAN, V6E 3V6
Website
Lophos Holdings Inc is engaged in the y is the cultivation of peyote and the manufacture of Lophophora compounds, including Mescaline, as well as formulation of novel Lophophora-based compounds.
Executives
John Ioannis Karagiannidis Director
Evan Stawnyczy Director

Lophos Holdings Headlines

No Headlines